Rhythm Pharmaceuticals, INC 10-Q quarterly reports

Rhythm Pharmaceuticals announced a 47% year-over-year increase in product revenue for Q2 2026, driven by strong sales of IMCIVREE, though net losses widened.

Rhythm Pharmaceuticals reports significant revenue growth and positive clinical trial results for its lead assets, extending its cash runway for at least 24 months.

Rhythm Pharmaceuticals reports significant revenue growth for IMCIVREE and positive Phase 3 clinical trial results for setmelanotide in hypothalamic obesity, bolstering its financial position with a recent $189.2 million capital raise.

Rhythm Pharmaceuticals announces Q1 2025 financial results, highlighting increased IMCIVREE sales and positive Phase 3 data for setmelanotide in acquired hypothalamic obesity.

Rhythm Pharmaceuticals' Q3 2024 results show a 48% increase in product revenue compared to the same period last year, driven by sales of IMCIVREE.

Rhythm Pharmaceuticals filed an amendment to its June 30, 2024 quarterly report to disclose Rule 10b5-1 trading plans adopted by three company insiders.

Rhythm Pharmaceuticals saw a significant increase in product revenue in the second quarter of 2024, but ongoing research and development expenses contributed to a net loss.

Rhythm Pharmaceuticals' Q1 2024 results show increased product revenue but also a significant net loss due to strategic investments and R&D expenses.